$AstraZeneca (AZN.US)$ AdCom for IMFINZI (durvalumab) tomorr...

AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️

» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)

Briefing docs for Thursday’s AdCom posted yesterday…

⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure

⏰ Meeting begins Thursday, 9 a.m. ET.